Key Takeaways
- DSOs evaluate practices using two distinct sets of financial requirements: practice-side thresholds (collections scale, adjusted EBITDA, payer mix, hygiene production, provider concentration) and buyer-side capacity (committed financing, PE backing, rollover equity, earnout funding).
- As noted throughout this article, practices typically need at least $1M–$1.5M in collections and 18%+ EBITDA margins to attract competitive DSO interest, with hygiene above 30% of collections and low provider concentration supporting stronger multiples.
- DSO deal structures often include 15–30% rollover equity and earnouts, so sellers may receive only 60–80% cash at close, with the balance tied to future performance and DSO recapitalization.
- Buyer-side risk can be easy to underestimate, so sellers benefit from verifying committed financing, PE dry powder, and the DSO’s post-close track record before signing, because weak buyers can stall or re-trade deals.
- McLerran & Associates provides diligence-grade EBITDA analysis, vets buyers, and negotiates structures that can protect seller proceeds.
Get a free consultation to assess your practice’s readiness.
The Practice-Side Financial Requirements DSOs Screen For
Institutional buyers apply a consistent set of screening criteria before a practice enters a competitive process. These criteria shift with specialty, geography, and buyer type, but the categories below represent the core underwriting variables a DSO evaluates.
- Collections And Revenue Scale. DSO and institutional buyers typically focus on practices above roughly $1 million to $1.5 million in collections, and rarely run competitive processes for practices below that level. Practices below that range usually fall back to private-buyer valuation methods. Above that threshold, scale becomes a multiple driver rather than just a qualifier.
- EBITDA And EBITDA Margin. EBITDA, or earnings before interest, taxes, depreciation, and amortization, means the practice’s operating profit before those non-cash and financing items are deducted. A DSO-interest sweet spot of approximately $1.5 million to $5 million in collections combined with an EBITDA margin above 18% is commonly cited. Margin thresholds can determine whether institutional buyers remain engaged through the process.
- Adjusted EBITDA And Add-Backs. Adjusted EBITDA normalizes reported earnings by adding back the owner-dentist’s above-market compensation and removing personal, discretionary, and non-recurring expenses. Owner-doctor production compensation normalized to a market clinical rate, typically 28% to 32% of production for a general practitioner, often produces $80,000 to $300,000 in normalized EBITDA uplift for solo-producer practices. This line is usually the most contested item in quality-of-earnings analysis. Other common adjustments include family members on payroll, personal vehicle expenses, and above- or below-market rent paid to a related party.
- Payer Mix And Medicaid Exposure. The mix of fee-for-service, PPO, and government-program revenue directly affects how a buyer models reimbursement risk. Practices with 40% or more of collections from Medicaid or HMO plans can face multiple compression of 0.5x to 1.0x as buyers price in reimbursement rate volatility and managed-care re-credentialing complexity.
- Accounts Receivable. Buyers examine AR aging, collection efficiency, credit balances, and whether AR transfers to the buyer or stays with the seller at close. On a practice collecting $2 million a year, AR alone can represent $150,000 to $250,000. This amount is a material working-capital item that affects net proceeds even when it does not change the headline enterprise value.
- Hygiene Production Percentage. Hygiene revenue signals recurring-revenue durability. Hygiene revenue above 30% of collections is associated with premium multiples and stronger DSO offers. Buyers typically request hygiene reappointment rate, 6‑month recall compliance, and hygiene-to-restorative conversion rate during diligence.
- Provider Concentration. Key-person risk, meaning how much production walks out the door with the selling dentist, is a primary underwriting variable. A practice where one provider produces 60% or more of collections can face a key-man discount that reduces enterprise value by 15% to 25% relative to a practice with production distributed across multiple providers.
- Operability, Facility, And Lease Terms. Remaining lease term, assignment rights, renewal options, and deferred technology capital expenditure all factor into the buyer’s model. DSO acquirers can discount enterprise value by 0.25x to 0.5x for deferred technology capital expenditure. This discount reflects an estimated post-close equipment upgrade cost for practices lacking cone-beam CT, digital impressions, or modern practice management software.
- Doctor Work-Back Willingness. Post-close clinical commitment functions as a price lever. Buyers pay materially more when the dentist agrees to 2 or more years of clinical work-back because it preserves the patient base through the transition and reduces earnout risk.
These are screening criteria, not a fixed table, and specialty and region shift what buyers expect. Because the thresholds move, a practice’s actual position against them requires careful analysis. McLerran & Associates has evaluated more than 10,000 dental practices and builds the CPA-led EBITDA analysis that determines where a practice actually lands against these requirements. This diligence-grade work happens before the deal goes to market so the numbers hold when buyers scrutinize them.
Find out where your practice lands against DSO financial requirements.
The Buyer-Side Financial Requirements DSOs Must Meet
While the practice-side criteria determine whether a practice qualifies, the buyer-side requirements determine whether the DSO can actually close the deal. The financial requirements a DSO has for buying practices include what the DSO itself must have in place to complete an acquisition. Seller risk is most underestimated on this side of the equation, which is often missing from standard practice-side benchmarks.
A DSO’s capacity to close and pay draws from several capital sources. Each source affects how much cash the seller actually receives and when.
Cash On Hand And Committed Institutional Debt fund the cash-at-close component of the purchase price. Lenders structure DSO acquisition capital as acquisition term loans, revolving lines of credit, and layered combinations of senior debt and mezzanine capital. Lenders generally look for a track record of practice-level profitability, a clear management structure, and reasonable leverage relative to consolidated EBITDA before extending financing. A DSO without committed financing, or one whose lender covenants are already strained, can stall, re-trade, or fail to close entirely.
Private-Equity Backing And Dry Powder, meaning the uncommitted capital a PE sponsor has available to deploy, can determine whether the DSO can fund acquisitions without returning to lenders for each deal. From 2023 to 2026, debt costs for DSO acquisitions ran roughly 9.5% to 11%, and only operators who can create EBITDA rather than simply buy it are positioned to service that debt and generate returns for equity holders. A DSO that grew on cheap capital without building operational infrastructure presents a materially different counterparty than one with a well-capitalized, experienced PE sponsor.
Rollover Equity Obligations affect how much of the purchase price is actually paid in cash and how much the buyer must fund. A DSO’s ability to fund the cash portion of a deal depends on its capital structure. Rollover equity, while a component of the purchase price, also functions as a buyer-side tool that reduces the cash the DSO must raise. DSO deal structures typically include 15% to 30% rollover equity, often described as effectively mandatory in DSO structures, with a hold period of 3 to 7 years to the next sponsor recapitalization. As much as 40% of a DSO deal can be paid in equity rather than cash, which means the seller is simultaneously a seller, a partner, and an investor in the acquiring organization. That equity is only as valuable as the DSO’s financial health and the PE sponsor’s ability to execute a future recapitalization.
Earnout Funding is a separate buyer-side obligation. The DSO must have the cash to pay earnouts when targets are met. However, the DSO also controls the accounting that determines whether targets are met. Management fees, allocated overhead, and intercompany charges can reduce a practice’s reported EBITDA by 15% to 40% depending on the DSO group. These charges directly shrink the base used to calculate earnout payments, even when the seller performs exactly as agreed.
Buyer capacity is a seller-side risk. A practice can be busy, productive, and clinically healthy while the organization above it is financially stressed, and lenders are paid according to the capital structure rather than according to how well the practice performs. McLerran & Associates underwrites the buyer like an investment, examining profitability, growth at existing offices, management strength, and the PE sponsor’s track record.
For a deeper look at how to research and vet a DSO before signing, see How To Vet A DSO Before Selling Your Dental Practice.
How A DSO Underwrites A Practice And Why The Number Moves
A DSO’s underwriting process begins with reported collections and works toward a buyer-accepted adjusted EBITDA figure. The gap between the seller’s number and the buyer’s number is where headline prices can get re-traded.
The buyer starts with trailing collections and tests how reliably those collections convert to cash that survives the owner’s departure. The buyer then normalizes owner and associate compensation to market rates. Personal, discretionary, and non-recurring expenses are added back, but only those that are documented and genuinely non-recurring. A “one-time” expense that appears in 3 consecutive years is unlikely to be accepted as a nonrecurring add-back by a buyer’s diligence team.
The buyer then layers in working capital requirements, existing debt obligations, capital expenditure needs, and lease obligations. At DSO valuation multiples of 6x to 7x EBITDA, every $100,000 change in accepted EBITDA moves the headline purchase price by roughly $600,000 to $700,000. This arithmetic helps explain why the quality-of-earnings process, the formal review in which the buyer’s team verifies and challenges the seller’s EBITDA, is where much of the value can be won or lost.
McLerran & Associates completes this diligence-grade work up front, before the deal goes to market, so the valuation is more likely to hold under buyer scrutiny and the agreed price is less likely to be renegotiated down. For a detailed look at what DSO buyers screen for in a practice, see DSO Buyer Requirements For Dental Practices (2026).
Control the narrative around your EBITDA before diligence starts.
How The Purchase Price Is Structured And What You Really Keep
A DSO purchase price functions as a package of components with different risk profiles and tax treatments. Understanding the structure can help you compare offers accurately.
Cash At Close is the guaranteed portion. DSO offers typically lead with 60% to 80% of the value as cash at close, with the balance rolled into joint-venture or holding-company equity. Cash at close is reduced by practice debt payoff, deal costs, and any working-capital true-up negotiated at the LOI stage.
Rollover Equity can be held at the joint-venture level, which tracks the seller’s own practice or regional group, or at the holding-company level, sometimes called the “second bite.” The value depends on when the seller enters the buyer’s hold period and the health of the buyer’s balance sheet. DSOs typically buy practices at one multiple but value their own equity at a higher multiple. As a result, a dentist who rolls proceeds into DSO equity has effectively paid a premium for that equity. A future recapitalization must occur at an even higher premium before the rollover investor breaks even.
Earnouts are deferred payments contingent on post-close performance, typically over 12 to 36 months. The buyer controls the staffing, marketing, scheduling, and overhead allocations that determine whether the target is hit. Tiered earnout structures may pay partial consideration at 80% of target and full payment at 100%. Binary structures pay nothing unless the threshold is met, and that difference can easily reach 6 figures over a 2‑year earnout period.
Tax Treatment varies by component. More than 76% of a dental practice’s purchase price typically flows to goodwill for tax-allocation purposes, taxed at long-term capital gains rates of 23.8% federal rather than the ordinary income rates that apply to equipment recapture and non-compete payments. Structure changes real after-tax proceeds even when the headline number looks identical. Consult a CPA with dental transaction experience before accepting any allocation.
McLerran & Associates produces multi-year, multi-structure financial forecasting across 3-, 5-, 7-, and 10-year horizons so owners can compare real proceeds across deal structures. The firm also negotiates non-punitive earnout terms, including pro-rata provisions so a near-miss on an EBITDA target still pays most of the earnout.
How To Verify A DSO’s Financial Capability Before Signing
Before entering exclusivity with any buyer, a seller can ask the DSO to substantiate its capacity to close. The following questions can serve as a starting checklist.
- Is the financing committed or contingent on future lender approval?
- Has the investment committee formally approved this acquisition?
- What percentage of the purchase price is cash at close versus rollover equity or earnout?
- Can the DSO provide references from dentists who sold to them in the prior 24 months?
- What happens contractually if financing falls through after the LOI is signed?
- How is the earnout funded, and who controls the accounting that determines whether targets are met?
The DSO will spend weeks going through a seller’s tax returns, production, collections, payroll, leases, and payer mix, so sellers can apply similar scrutiny to the buyer. McLerran & Associates vets buyers before they reach the table, examining debt load, interest coverage, same-store EBITDA growth, management quality, and the PE sponsor’s track record.
DSO Versus Private-Buyer Financial Requirements
DSO buyers and private doctor-to-doctor buyers underwrite dental practices using fundamentally different frameworks, and the gap between them can be substantial on the same practice.
DSO buyers underwrite on a multiple of adjusted EBITDA and require scale, typically collections above a minimum threshold and EBITDA margins that support institutional returns. Practices below roughly $250,000 of post-doctor-compensation adjusted EBITDA rarely attract competitive DSO processes. The DSO’s financing is institutional, with layered debt, PE equity, and rollover obligations, and the deal structure reflects that complexity.
Private doctor-to-doctor buyers are typically evaluated on a percentage of trailing collections or a multiple of seller’s discretionary earnings (SDE, which means net income plus owner compensation, owner discretionary expenses, non-recurring items, and depreciation). General dental practices in private sales have traded at 65% to 85% of annual gross collections, with financing typically provided through SBA 7(a) or conventional dental-specific lender programs. Private-buyer deals are almost always straightforward asset purchases with no rollover equity, no multi-year earnout, and no management services agreement.
The practical implication is that the same practice can have a materially different value in each market, and the right path depends on the practice’s size, profitability, and the owner’s goals. Because McLerran & Associates works both paths in roughly equal measure, it produces a true side-by-side valuation so an owner can see their worth in both markets before choosing.
See your practice’s worth in both the DSO and private-buyer markets.
Frequently Asked Questions
What EBITDA Does A DSO Require?
DSO and institutional buyers generally require a minimum level of post-doctor-compensation adjusted EBITDA before running a competitive process, and practices below that floor typically fall to private-buyer methods. Above the floor, the EBITDA multiple a buyer applies varies with practice size, specialty, payer mix, provider concentration, hygiene durability, and market conditions. Larger, associate-led, fee-for-service-heavy practices with stable trailing results tend to command higher multiples. Smaller, owner-dependent, Medicaid-heavy practices compress toward the lower end of the range. No specific multiple can be promised, because the right number is determined by your specific practice’s fundamentals and the competitive process among buyers.
How Much Does A DSO Need To Buy A Practice?
A DSO funds an acquisition through a combination of cash on hand, committed institutional debt such as acquisition term loans, revolving credit facilities, and sometimes mezzanine capital, private-equity sponsor equity, and in some cases bridge financing. The cash-at-close component is funded by senior debt plus PE equity, while rollover equity obligations and earnout funding function as separate buyer-side commitments. A DSO’s ability to close depends on whether its financing is committed rather than contingent, whether its lender covenants have headroom, and whether its PE sponsor has sufficient dry powder, meaning uncommitted capital available to deploy. Sellers can ask for evidence of committed financing before entering exclusivity.
Are DSOs Private Equity?
Most large DSOs are backed by private equity sponsors but are not themselves PE firms. The typical structure pairs a dentist-owned professional corporation, which holds the dental license and employs clinical staff as required by most states’ corporate-practice-of-dentistry laws, with a DSO or management services organization that holds non-clinical assets and provides business support under a management services agreement. The PE sponsor owns equity in the DSO management entity, not the clinical practice. Some DSOs are doctor-owned or employee-owned without outside PE backing, and their capital structures, acquisition capacity, and recapitalization timelines can differ materially from PE-backed platforms.
Conclusion: See Both Sides Before You Negotiate
The financial requirements in a DSO acquisition run in both directions. The practice-side thresholds, including collections scale, adjusted EBITDA and margin, payer mix, accounts receivable, hygiene production, provider concentration, lease terms, and work-back willingness, can determine whether a practice qualifies for institutional interest and at what multiple. The buyer-side requirements, including committed financing, PE backing and dry powder, rollover equity obligations, and earnout funding, can determine whether the deal actually closes and how much of the headline number the seller keeps.
Understanding both sides gives an owner leverage in negotiations, while focusing only on practice-side criteria can leave them at a disadvantage.
McLerran & Associates is the dental-only sell-side advisor and advocate that controls the EBITDA narrative, creates competition among vetted buyers, typically generating around 10 offers in a 45- to 60-day process, and verifies buyer capacity before a client signs anything. With roughly 2,000 successful practice sales, approximately $2 billion in closed transaction volume, and more than 10,000 practices evaluated, the firm brings both sides of the table into focus so owners can approach one of the most consequential financial decisions of their careers with fuller information.
If you have not yet decided whether to sell or which path is right for you, the McLerran M&A Summit (October 29–30, 2026) is built for owners at exactly that crossroads. The event offers education, one-on-one CPA sessions, and a complimentary practice valuation before you commit to anything.
Schedule a free, confidential discovery call with McLerran & Associates.
